39503-51-0

Basic information

• Product Name: 5-Bromo-2-methylbenzenamine
• Synonyms: 5-Bromo-2-methylbenzenamine;Methyl 5-broMo-2,4-diMethoxybenzoate;2,4-Dimethoxy-5-bromobenzoic acid methyl ester;5-Bromo-2,4-dimethoxybenzoic acid methyl ester;Methyl 2,4-dimethoxy-5-bromobenzoate;Benzoic acid,5-bromo-2,4-dimethoxy-, methyl ester
• CAS NO: 39503-51-0
• Molecular Formula: C₁₀H₁₁BrO₄
• Molecular Weight: 186.05
• Mol File: 39503-51-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 117℃
• Boiling Point: 349.1 °C at 760 mmHg
• Flash Point: 164.9 °C
• Appearance: /
• Density: 1.436
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Bromo-2-methylbenzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-2-methylbenzenamine(39503-51-0)
• EPA Substance Registry System: 5-Bromo-2-methylbenzenamine(39503-51-0)

Safety Data

• Hazardous Substances Data: 39503-51-0(Hazardous Substances Data)

Usage

Chemical Properties

light yellow solid

Upstream product

• 67-56-1 methanol 
• 32246-20-1 5-bromo-2,4-dimethoxybenzoic acid 
• 39503-52-1 methyl 5-bromo-2-hydroxy-4-methoxybenzoate 
• 77-78-1 dimethyl sulfate 
• 89-86-1 4-hydroxysalicylic acid 
• 7355-22-8 5-bromo-4-hydroxysalicylic acid 
• 70752-22-6 methyl 5-amino-2,4-dimethoxybenzoate 
• 74-88-4 methyl iodide 
• 2150-41-6 methyl 2, 4-dimethoxybenzoate 
• 75-36-5 acetyl chloride 

Downstream Products

• 1026712-08-2 C₂₀H₂₂O₈ 
• 39503-52-1 methyl 5-bromo-2-hydroxy-4-methoxybenzoate 
• 148014-09-9 5-(3-carboxy-4-methoxy-5-methylphenoxy)-2,4-dimethoxybenzoic acid 
• 1026702-55-5 C₁₈H₁₆Cl₂O₆ 
• 913000-27-8 5-isopropenyl-2,4-dimethoxy-benzoic acid methyl ester 
• 949465-78-5 methyl 5-(3-chloro-2-fluorobenzyl)-2,4-dimethoxybenzoate 

Relevant articles and documents

Discovery of Potent Non-Nucleoside Inhibitors of Dengue Viral RNA-Dependent RNA Polymerase from a Fragment Hit Using Structure-Based Drug Design

The discovery and optimization of non-nucleoside dengue viral RNA-dependent-RNA polymerase (RdRp) inhibitors are described. An X-ray-based fragment screen of Novartis fragment collection resulted in the identification of a biphenyl acetic acid fragment 3, which bound in the palm subdomain of RdRp. Subsequent optimization of the fragment hit 3, relying on structure-based design, resulted in a >1000-fold improvement in potency in vitro and acquired antidengue activity against all four serotypes with low micromolar EC50 in cell-based assays. The lead candidate 27 interacts with a novel binding pocket in the palm subdomain of the RdRp and exerts a promising activity against all clinically relevant dengue serotypes.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound for use in medicine, the compound being a compound of the formula (VI0) or a salt, solvate, tautomer or N-oxide thereof: wherein the bicyclic group: is selected from the structures C1, C5 and C6: wherein n is 0, 1, 2 or 3; R1 is hydrogen, hydroxy, or O—Rz; R2a is hydroxy, methoxy or O—Rz; provided that at least one of R1 and R2a is O—Rz; Rz is Lp-Rp1; SO3H; a glucuronide residue; a mono-, di- or tripeptide residue; or Lp is a bond, C═O, (C═O)O, (C═O)NRp1 or S(O)xNRp1; x is 1 or 2; Rp1 is hydrogen or a an optionally substituted C1-25 hydrocarbyl group containing 0, 1 or 2 carbocyclic rings and 0, 1, 2, 3, 4, 5 or 6 carbon-carbon multiple bonds, provided that Rp1 is not hydrogen when Lp is a bond, C═O or (C═O)O; and provided also that O—Rz does not contain an O—O moiety; and excluding compounds wherein R1 is hydroxy and R2a is methoxy; Rp2 and Rp3 are the same or different and each is a group Rp1; and R3, R4a, R8 and R10 are defined in the claims. The compounds of formula (VI0) are pro-drugs of parent compounds wherein R1 and/or R2a are hydroxy, wherein the parent compounds have Hsp90 inhibiting activity.

PHARMACEUTICAL COMBINATIONS

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1- 5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.